MAM
Hogarth crafts Dove’s ‘Reborn Collective’ as a culture-first campaign
MUMBAI: Hogarth India has partnered with Dove to launch The Reborn Collective, the brand’s first long-format cultural platform, positioning strength as something forged through lived experience rather than polished perfection.
Rooted in Dove’s new Peptide Bond Strength haircare range, the campaign draws on the idea of hair being “reborn stronger” through bond repair using peptides. That product truth is expanded into a broader cultural metaphor inspired by kintsugi: the Japanese art of repairing broken objects with gold, where damage is acknowledged and transformed into strength.
Developed by Hogarth’s creative team, the platform translates Dove’s “reborn stronger” philosophy into a series of intimate, human-first conversations and collaborations. Anchored in repair rather than erasure, the collective brings together eight women whose personal journeys reflect resilience shaped over time: Neena Gupta, Sunita Rajwar, Zeenat Aman, Trinetra Haldar, Geeta Tandon, Rhea Chakraborty, Aditi Parmeshwaran and Baljeet Kaur.
The initiative unfolds through Reborn stronger: the podcast, featuring four candid episodes with members of the collective, and Reborn stronger: the anthem, Jugni: a musical ode to renewal composed by Sneha Khanwalkar, written by Anvita Dutt and sung by Afsana Khan and Raja Kumari. With rustic, desi and sufi influences, the anthem pushes the idea of rebirth beyond narrative into sound and emotion.
“Transformation is not about erasing the past, but embracing and repairing it,” said Hindustan Unilever vice president, hair care Sairam Subramanian. “The Reborn Collective captures the real, raw moments that shape who we become.”
Hogarth India beauty vertical head Sunetro Lahiri, said the campaign was a conscious move away from overt digitisation towards something more human, while Ishita Hora, vice president, client services at Hogarth Mumbai, described it as a rare opportunity to build a cultural platform grounded in truth rather than surface storytelling.
Designed to live across platforms and invite participation, The Reborn Collective opens the conversation to women nationwide, encouraging them to share their own moments of renewal, positioning rebirth not as a comeback, but as an ongoing, deeply personal process.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
